(rivaroxaban)
This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
XARELTO® (rivaroxaban)
Medical Information
XARELTO - Reversal Agents in Human Studies - aPCC and PCC - Escolar et al (2015)
Last updated : 05/16/2024
Escolar et al (2015) evaluated the reversal of XARELTO-induced (20 mg) alterations on hemostasis using PCC (Beriplex® 50 IU/kg), aPCC (FEIBA 75 U/kg), and rFVIIa (NovoSeven® 270 µg/kg) in 8 healthy volunteers.1
- Thrombin generation and TEM parameters were measured, and modifications in platelet adhesive, aggregating, and procoagulant activities were evaluated using circulating blood.
- The concentrates (rFVIIa ≥ aPCC > PCC) improved prolonged clotting times and reduced clot firmness caused by XARELTO on TEM tests.1
- Reductions in fibrin formation were partially restored by the concentrates (rFVIIa > aPCC ≥ PCC).1
aPCC, activated prothrombin complex concentrate; PCC, prothrombin complex concentrate; rFVIIa, recombinant factor VIIa; TEM, thromboelastometry.
Reference
Show Hide
1. Escolar G, Arellano-Rodrigo E, Lopez-Vilchez I, et al. Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates – in vitro studies with steady and circulating human blood. Circ J. 2015;79(2):331-338.
